A detailed history of Trifecta Capital Advisors, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Trifecta Capital Advisors, LLC holds 14 shares of MRNA stock, worth $575. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 14 -0.0%
Holding current value
$575
Previous $1.66 Million 43.72%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 25, 2024

BUY
$69.51 - $104.43 $973 - $1,462
14 New
14 $1.39 Million
Q2 2023

Aug 14, 2023

BUY
$118.5 - $160.53 $1,540 - $2,086
13 New
13 $1.58 Million
Q4 2022

Jan 17, 2023

BUY
$118.38 - $210.04 $710 - $1,260
6 New
6 $1.08 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $16.1B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Trifecta Capital Advisors, LLC Portfolio

Follow Trifecta Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trifecta Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trifecta Capital Advisors, LLC with notifications on news.